New NHS Weight Management Medication – Tirzepatide (Mounjaro®)

Posted on:

NHS England and NICE have approved the use of Tirzepatide, also known as Mounjaro® or sometimes referred to as ‘the weight loss drug’, for use in primary care.

You may hear that Tirzepatide will be available from primary care starting 23rd June 2025. However, NHS England has introduced strict eligibility criteria for the first two years to ensure the safe and controlled rollout of this medicine.

Please only contact the practice if you meet both of the following:

  • You have a BMI of 40 or higher
  • You have already been diagnosed with at least four of the following conditions by your GP or another medical professional:
  1. Hypertension
  2. Dyslipidaemia
  3. Obstructive sleep apnoea
  4. Atherosclerotic Cardiovascular Disease (ASCVD)
  5. Type 2 diabetes mellitus

Thank you for your understanding and support as we follow national guidance on this new treatment.